Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cytotherapy|August 23, 2022
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trialSara Azhari Mohamed, Aoife Duffy, Veronica McInerney, et al.
Familial Cancer|August 9, 2014
Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutationsStephen E Langabeer, Karl Haslam, Jennifer Linders, et al.
Cancer Research|October 15, 2009
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemiaAnthony M McElligott, Elaina N Maginn, Lisa M Greene, et al.
Cytotherapy|April 11, 2020
Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalitiesSara Azhari Mohamed, Linda Howard, Veronica McInerney, et al.
Irish Journal of Medical Science|May 20, 2020
COVID-19 in adults: test menu for hospital blood science laboratoriesPaula M O'Shea, Graham Robert Lee, Tomás P Griffin, et al.
Leukemia & Lymphoma|September 20, 2017
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLLNiamh Appleby, David O'Brien, Fiona M Quinn, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2021
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaVincent Ribrag, Seung Tae Lee, David Rizzieri, et al.
Frontiers in Oncology|July 15, 2022
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre StudyMark A Catherwood, Dorte Wren, Laura Chiecchio, et al.
British Journal of Haematology|May 7, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysisAlexandros Rampotas, Matthew R Wilson, Oliver Lomas, et al.
Bone Marrow Transplantation|January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTMeral Beksac, Diderik-Jan Eikema, Linda Koster, et al.
Pageof 3